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1002-41 Is Recurrent Myocardial Infarction Following 
Thrombolyttc Administrat ion Associated With Long- 
Term Mortality? 
Michael Gibson. Sabina A. Murphy, David James, Graham Wong, Christopher P, 
Cannon, Robert P. Giugliano, Elliott M. Antman, Eugene Breunwald, Harvard Clinical 
Research Institute, Boston, Massachusetts, Brigham & Women's Hospital, Boston, 
Massachusetts. 
Background: While early recurrent MI (re MI) after thrombolytic therapy has been asso- 
ciated with higher short-term mortality in acute MI, its relationship to long-term mortality 
has not been explored. We hypothesized that re MI would be associated with higher mor- 
tality at both 30 days and 2 years due to the association of reMI with lower EF, more CHF, 
and more SCD/CHF death, Methods: 30 day mortality was ascertained in the InTIME-II 
trial and the TIMI 4, 9A, 9B, and 10B acute MI triels. 5122 patients had followup <1 yr, 
14379 patients had data from 1 yr to <2 years, and 598 had >=2 years, but all data after 
2 yrs was censored at 2 yrs. Results: The frequency of re MI dudng the index hospital- 
ization was 4.16% (836/20101) in the five trials. Mortality by 30 days was increased in 
patients who experienced re MI during the index hospitalization (16.4%, 137/836 vs 
6.17%, 1188/19260, p<0.001). Long-term mortality remained higher in patients sustain- 
ing re MI, even after adjusting for age, anterior MI, pulse on admission, and gender (Haz- 
ard ratio=2.07, p<0.001, Figure). However, in an analysis restricted to patients who 
survived the index hospitalization, long-term mortality was not significantly higher in 
patients who had an early reinfarction (4.38%, 31/707 vs 3.76%, 685/18206, p=NS). 
Conclusion: Early re MI is associated with increased mortality at 2 years. However, 
most deaths occur early, and the dsk of additional deaths between the index hospitaliza- 
tion and 2 years did not appear to be increased. 
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1002-42 International Differences in Patients, Care, and 
Outcomes Associated With Acute Myocardial 
Infarction: The HERO-2 Trial 
John Simes. Harvey D. White, lan C. Marschner, Ssrgei Varshavsky, Rafeal Diaz, Robert 
G. Wilcox, Paul W. Armstrong, Chris B. Granger, John K. French, Frans Van de Werf, 
Philip E. Aylward, for the HERO-2 Investigators, NHMRC Clinical Trials Centre, 
University of Sydney, NSW, Australia, Greenlane Hospital, Auckland, New Zealand. 
Background HERO-2 compared the direct thrombin inhibitor, bivalirudin and streptoki- 
nase (SK) with unfrectionatad heparin and SK in 17,073 patients with evolving AMI pre- 
senting within 6 hours. Btvalirudin treatment significantly reduced in-hospital reinfarction 
(odds ratio 0.77 (95% CI 0.65-0.92) p=0.004) with a nonsignificant effect on 30-day mor- 
tality (odds ratio 0.96 (85% CI 0.66, 1.07) p=0.46).* 
Methods International differences in patient profile, care and outcomes were compared 
across 49 countries grouped in 5 regions: Western countries (West), Latin America (Latin 
Am), Eastern (E) Europe, Russia and Asia, for all randomized patients and for a repre- 
sentative sample of screened patients (n= 1774). 
Results A much higher percentage of eligible patients were randomized from eastern 
regions with more patients with antedor MI, poor Killip class and late presentation. Rela- 
tively more old patients were enrolled from the West. However, overall risk profile was 
similar across regions. Patients from E. Europe and Russia had lower rates of coronary 
intervention and stayed longer in hospital. 30-day mortality was 6.7% in Western coun- 
tries but 10-13% in eastern regions. 
Conclusions There was significant variation in 30-day mortality across regions, even 
after adjustment for patient risk profile.* However, similar relative treatment effects of 
bivalirudin were seen across re,lions, reinforcing) the wide applicability of the trial results. 
Region West Latin Am E. Europe Russia Asia 
Randomized (n=) 2563 1820 5877 6057 756 
% Randomized of eligible pts 11 17 54 69 37 
Age >75 years (%) 18 10 12 13 4 
Anterior MI (%) 32 43 44 51 52 
Symptoms >4 hours (%) 20 32 27 32 41 
Killip class Ill/IV (%) 1.4 1.8 3.4 6.7 1.2 
Median GUSTO risk score 60 58 61 62 55 
Median Days in hospital 7 7 13 22 6 
In-hospital PCI (%) 18.3 10.3 3.4 0.3 9.9 
30-day mortality (%) 6.7 10.8 10.2 13.2 11.0 
* Analyses adjusted for gender and baseline risk factors. 
JACC March 6, 2002 
1002-43 Coronary Artery Passivstion: A Mechanism for the 
Prevention of Recurrent Ischemia After Thrombolysis 
Mark H. Rubensteiq, Harry D. Garabedian, Luis Guerrero, Suzanne M. Sullivan, Thomas 
Aretz, Renu Virmani, Stanley Hollenbach, Robert C. Leinbach, Herman K. Gold, 
Massachusetts Genera//-/ospita/, Boston, Massachusetts, Cot Therapuetics, Inc., South 
San Francisco, California. 
Background: Combination therapy with reduced dose plasminogen activator and full 
dose platelet glycoprotein lib/Ilia receptor blockade significantly reduces recurrent 
ischemia after myocardial infarction. This clinical benefit may result from coronary artery 
passivation, defined as the inability to recruit new platalets to the site of endothelial dis- 
ruption. We sought to determine whether combination therapy induces rapid coronary 
artery passivation following successful thrombolysis. Methods: Using scanning electron 
microscopy (SEM), we examined platelet and fibdn accumulation in a canine model of 
acute myocardial infamtion. Occlusive left anterior descending coronary artery thrombo- 
sis was produced after endothelial disruption in the presence of a superimposed >90% 
distal stenosis. Animals were treated with either Eptifibatide (Ep) alone (n=11) or Ep + rt- 
PA (n=11). Ep was infused at a dose of 0.5 mg/kg + 6 p.g/kg/min IV for 90 min and rt-PA 
was given at a reduced dose of 0.45 mg/kg IV. All animals received intravenous heparin 
(to maintain ACT > 250 sec) and aspirin (10 mg/kg). The coronary pathology was exam- 
ined at termination of Ep (T1) in 6 dogs from each treatment group and 2 hours after ter- 
mination of Ep (T2) in 5 dogs from each treatment group. Results: At T1, both Ep and Ep 
+ rt-PA SEM showed complete absence of mural platelet hrombus or platelet aggregates 
while Ep SEM demonstrated residual erythrocyte-rich mural thrombus. At T2, platalet 
aggregation had retumed to 86% of baseline and Ep levels were almost undetectable. 
SEM of all Ep + rt-PA dogs showed an intimal surface devoid of both adherent mural 
thrombus and platalet aggregates while SEM of all Ep dogs showed new platalet aggre- 
gates adherent to residual erythrocyte-rich clot. Conclusion: Combination therapy with 
plasminogen activator and high-level platalet glycoprotein lib/Ilia receptor blockade rap- 
idly passivates a recanalized coronary artery by cleadng both erythrocyte-rich and plate- 
let-rich thrombus components. Removal of both components results in persistent 
patency despite endothelial disruption, high-grade residual stenosis, and the return of 
platelet function to normal. 
1002-44 Impact of Enoxaparin and Abciximab on Bleeding 
Complications in Acute Myocardial Infarction: Insights 
From ASSENT-3 
Josaoh Demt, Paolo M. Fioretti, Jose L. Lopez-Sendon, Freak Verheugt, Jt3rgen Meyer, 
Paul Toutouzas, Lars Wallentin, Chris Granger, Paul Armstrong, Frans J. Van de Weft, 
University Hospital Gasthuisberg, Leuven, Belgium. 
In the ASSENT-3 trial the co-administration of abciximab (ABC) and half-dose tenect- 
eplase was associated with a significant increase in non-cerebral bleeding complications 
when compared with full-dose tenecteplase and ACC/AHA recommended doses of 
unfractionatad heparin (UFH). A non-significant trend towards more bleeding complica- 
tions was also observed with the combination of full-dose tenecteplase and sustained SC 
administration of enoxaparin (ENOX). We analyzed the incidence of spontaneous and 
puncture-related bleeding complications in the 3 treatment groups of ASSENT-3 (table). 
Conclusion: When compared with unfractionated heperin, abciximab but not enoxaparin 
increased the risk of spontaneous bleeding complications when given in association with 
tenecteplase. Neither abciximab nor enoxaparin induced more bleadings of the arterial 
puncture site. 
Bleeding Complications: At Puncture Bites or Spontaneous 
(As Treated Population) 
% ENOX ABC UFH p 
Puncture Related 
Arterial sites 5.45 4.55 5.21 0.402 
Venous sites 7.92 15.54 6.75 <0.0001 
Subcutaneous ites 
>5 cm 1.93 0.82 0.40 <0.0001 
<=5 cm 3.62 1.28 0.84 <0.0001 
Spontaneous 
Gastro-intestinal 2.72 4.91 2.04 <0.0001 
Genito-urinary 3.22 4.50 3.23 0.054 
Epistaxis 1.68 4.04 1.74 <0.0001 
Gum 3.42 15.29 3.33 <0.0001 
Retropedtoneal 0.30 0.15 0.15 0.622 
